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ABSTRAK 
 
Latar belakang: Penyakit pendarahan saluran cerna bahagian atas bukan variseal (NVUGIB) 
adalah suatu penyakit yang kerap ditemui dan merupakan sebab utama kematian dalam kalangan 
lebih kurang 5-10% pesakit. Transfusi sel darah merah (RBC) merupakan salah satu kaedah 
perawatan bagi pesakit yang menghidap NVUGIB. Walau bagaimanapun, transfusi RBC dikaitkan 
dengan pelbagai morbiditi dan kematian. Kajian in bertujuan untuk mencari perkaitan antara 
simtom, aetiologi dan Skor Glasgow-Blatchford (GBS) dengan bilangan unit transfusi RBC. 
Selain daripada itu, kajian ini bertujuan untuk membandingkan kesan terhadap paras discaj Hb 
yang berbeza dalam kalangan pesakit NVUGIB di Hospital Putrajaya. 
 
Kaedah: Kajian kohort retrospektif dilakukan kepada data daripada 180 pesakit NVUGIB yang 
telah ditransfusi dengan RBC dalam tempoh lima tahun. Data diambil daripada sistem informasi 
pesakit berkomputer Hospital Putrajaya. Subjek kajian dipilih diisi dalam proforma. Kesemua data 
demografi dan klinikal termasuk simtom-simtom awal seperti melaena, haematemesis, 
haematochezia dan anaemia direkodkan. Selain simtom awal tersebut, pembolehubah-
pembolehubah lain juga dikaji termasuk aetiologi NVUGIB, GBS, dan bilangan unit RBC yang 
ditransfusi. Kesan-kesan klinikal terhadap dua kumpulan paras discaj Hb yang berbeza 
dibandingkan. 
 
Keputusan: Dalam kalangan 180 pesakit, 92 (51.1%) mempunyai paras discaj Hb < 10 g/dl 
manakala 88 (48.9%) mempunyai paras discaj Hb ≥ 10 g/dl. Regresi linear pelbagai mendedahkan 
bahawa hematochezia (p=0.022) dan GBS yang lebih tinggi (p<0.001) merupakan faktor-faktor 
xv 
 
yang dikaitkan secara bebas dengan bilangan unit transfusi RBC yang lebih tinggi. Dengan ujian 
Mann Whitney-U, pesakit dengan paras discaj Hb ≥ 10 g/dl menyumbang secara signifikan kepada 
bilangan unit transfusi RBC yang lebih tinggi (p=0.005) dan tempoh tinggal di hospital (LOS) 
yang lebih lama (p=0.029).  
 
Kesimpulan: Hematochezia dan GBS ialah dua faktor penentu yang penting untuk kebarangkalian 
bilangan transfusi RBC unit yang lebih banyak dalam kalangan pesakit NVUGIB. Pesakit dengan 
paras discaj Hb ≥ 10 g/dl dikaitkan dengan bilangan transfusi RBC unit yang lebih banyak dan 
LOS yang lebih lama. 
 
Kata kunci: NVUGIB, Transfusi RBC, Discaj Hb, GBS, Hematochezia 
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ABSTRACT 
 
Background: Non-Variceal Upper Gastrointestinal Bleeding (NVUGIB) is very common and 
with considerable 5-10% mortality. RBC transfusion is one of the treatments for NVUGIB patients 
but it is associated with various morbidity and mortality. This study was to determine the 
associations between number of RBC units transfused with presenting symptoms, aetiologies and 
Glasgow-Blatchford Score (GBS). This study also compared the outcomes of discharge at different 
level of Hb among NVUGIB patients at Hospital Putrajaya. 
 
Methods: Retrospective cohort study was performed with data from 180 patients with NVUGIB 
and were transfused with RBC over a period of five years. Data were retrieved from the 
computerised patient information system of Hospital Putrajaya. Study subjects selected were filled 
in the proforma. All demographic and clinical data including presenting symptoms such as 
melaena, haematemesis, haematochezia, and anaemia were recorded. Besides presenting 
symptoms, other variables studied include aetiologies of NVUGIB, GBS, and number of RBC 
units transfused. The clinical outcomes of patients with two different level of discharge Hb were 
compared.  
 
Results: Out of 180 patients, 92 (51.1%) had discharge Hb < 10 g/dl while 88 (48.9%) of them 
had discharge Hb ≥ 10 g/dl. Using multiple linear regression, haematochaezia (p=0.022) and 
higher GBS (p<0.001) were factors which were independently associated with higher number of 
RBC units transfused. Using Mann Whitney-U test, patients with discharge Hb ≥ 10 g/dl were 
xvii 
 
shown to be significant contributor to higher number of RBC units transfused (p=0.005) and longer 
length of stay (LOS) (p=0.029). 
 
Conclusion: Haematochaezia and GBS were two important determinants for the probability of 
higher need in RBC unit transfusion for NVUGIB patients. Patients with discharge Hb ≥ 10 g/dl 
will result in higher number of RBC units transfusion and longer LOS.  
 
Key words: NVUGIB, RBC transfusion, Discharge Hb, GBS, Haematochaezia 
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CHAPTER 1: INTRODUCTION 
 
1.1 Overview of Non-Variceal Upper Gastrointestinal Bleeding (NVUGIB) 
 
Gastrointestinal bleeding is a medical emergency which has been illustrated as the most frequent 
cause of hospitalisation linked to the digestive tracts in most countries (Gralnek et al., 2017; Lanas 
and Chan, 2017). Upper gastrointestinal bleeding (UGIB) is defined by gastrointestinal bleeding 
superior to the ligament of Treitz which consists of the stomach, duodenum and oesophagus. UGIB 
events can be further classified as non-variceal upper gastrointestinal bleeding (NVUGIB) and 
variceal upper gastrointestinal bleeding (VUGIB) (Sung et al., 2010). NVUGIB presented as 
haematemesis, melaena, haematochezia or other clinical or laboratory evidence of acute blood loss 
from the upper gastrointestinal tract confirmed by endoscopy (Lanas et al., 2011). 
 
NVUGIB is most frequently triggered by peptic ulcers which are linked with Helicobacter pylori 
infection and non-steroidal anti-inflammatory drugs (NSAIDs) therapy including aspirin. By 
definition, peptic ulcer is a disruption of the mucosal layer that opens up the submucosa to acid 
secreted in the gastroduodenal lumen. On the contrary, VUGIB is caused after the formation of 
oesophageal or gastric varices which are commonly linked with chronic liver disease and/or portal 
hypertension. NVUGIB is five times more likely compared to VUGIB in most countries. NVUGIB 
is a serious clinical challenge with significant 5-10% mortality to date (Sung et al., 2010). 
 
The United States recorded an incidence of NVUGIB nearly 67 per 100,000 individuals in 2012. 
The incidence of peptic ulcer bleeding encompasses around 32.1 per 100,000 individuals in 2009 
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(Lanas and Chan, 2017). In Europe, the incidence of NVUGIB is about 25-35 per 100000 
individuals in the early 2000s (van Leerdam et al., 2003). In Malaysia, the incidence is 
approximately 72 per 100000 for Sabah and Sarawak (Cheng et al., 2001). According to the 
Clinical Practice Guideline (CPG), bleeding peptic ulcer is the most frequent cause of acute 
NVUGIB nationally (MOHM, 2003).   
 
The risk factors that are associated with NVUGIB are the use of NSAIDs, smoking, alcohol 
consumption, anti-coagulant, traditional medication and steroids. A study of NVUGIB patients in 
Europe, revealed that 26.7% of them were smokers, 36.7% consumed alcohol, 34.5% had NSAIDs 
therapy, and 7.1% used anticoagulants (Garrido et al., 2006). One study of NVUGIB patients 
conducted in Hospital Kuala Lumpur (HKL) had shown that 50% were smokers, 37.5% consumed 
alcohol, 17.2% had NSAIDs therapy, 5.5% used traditional medications, 2.3%  anti-coagulants 
and 0.8% steroids (Lakhwani et al., 2000). The most commonly associated risk factor for NVUGIB 
in the European population was alcohol consumption. Meanwhile in Kuala Lumpur, smoking was 
the most significant risk factor identified among NVUGIB patients. 
 
The aetiologies of NVUGIB include peptic ulcer, erosive gastritis/duodenitis, Mallory-Weiss tear, 
neoplasms, angiodysplasia, oesophagitis/oesophageal ulcer, Dieulafoy’s lesions (aberrant vessels 
in the mucosa) and aortoenteric fistulas. The most frequent aetiology of NVUGIB was peptic ulcer 
disease (Ferguson and Mitchell, 2006). In a local study done in HKL, the aetiologies of NVUGIB 
include 61.7% peptic ulcer, 21.9% erosive gastritis/duodenitis, 3.9%  neoplasms and 1.6%  due to 
other causes (Lakhwani et al., 2000). 
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Forrest classification which was developed four decades ago classifies acute UGIB patients into 
low and high-risk categories for mortality. It is most widely used to classify the endoscopic 
appearance of bleeding peptic ulcers (Forrest et al., 1974). At this point in time, it is generally used 
to predict the risk of rebleeding as well as mortality (Guglielmi et al., 2002). The Forrest 
classification classifies ulcers with a spurting haemorrhage (Forrest Ia), an oozing haemorrhage 
(Forrest Ib), a visible vessel (Forrest IIa), an adherent clot (Forrest IIb), hematin on the ulcer base 
(Forrest IIc), and a clean ulcer base (Forrest III) (de Groot et al., 2014; Forrest et al., 1974).  
 
1.2 Blood Transfusion and NVUGIB 
 
UGIB is a significant cause of morbidity and mortality. It takes up a significant amount of health 
resources including the need of blood transfusion specifically packed red blood cells (RBC). Acute 
and persistent gastrointestinal bleeding will render the patient to have a high mortality rate ranging 
from 5 to 10%. Transfusion support is vital and one of the essential elements in treating these 
patients. Thus, it is routinely used in the gastroenterology departments (Garrido et al., 2006). It is 
a common indication for RBC transfusion because haemodynamic instability can diminish the 
delivery of oxygen to tissues and also the tissue perfusion. RBC transfusion may be lifesaving in 
patients who are actively haemorrhaging.  
 
Nonetheless, in patients with stable UGIB, restrictive transfusion strategy could be more beneficial 
as it would significantly improve patient outcomes. This strategy will help in reducing the risk of 
rebleeding, the need for rescue interventions and complications. Thus, it improved the survival 
rate among UGIB patients (Villanueva et al., 2013). 
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Hospital Putrajaya is one of the tertiary medical centers in Malaysia. Statistics revealed that the 
number of oesophagogastroduodenoscopies (OGDS) performed in this hospital ranged from 400 
to 500 annually between 2010 to 2017. Among the patients who underwent OGDS, 5 to 8% of 
them received RBC transfusion. (Unpublished data of Hospital Putrajaya, 2017).  
 
1.3 Research Justification and Benefits 
 
This study aimed to evaluate the existing practice on RBC transfusion in NVUGIB patients and to 
suggest alternative approaches upon the outcomes that turn out not to be favourable to the patients. 
This study analysed their data profiling with regards to demographic characteristics, risk factors, 
presenting symptoms, aetiologies, Forrest classification and Glasgow-Blatchford Score (GBS). 
GBS is a screening tool to assess the likelihood that a patient with an acute UGIB will need to 
have medical intervention such as a blood transfusion or an endoscopy. Factors such as presenting 
symptoms, aetiologies and GBS may influence the number of RBC units transfused. Currently, 
there was no similar research on this subject matter in Malaysia. Hence, this study was done to 
evaluate the association between number of RBC transfused with these selected variables. 
Generally, this will improve the availability of local data in Malaysia and the profile of RBC 
transfusion practice among clinicians. The risk of rebleeding and the requirement of blood 
transfusion among NVUGIB patients vary. Identifying patients with higher risk and accelerating 
their interventions are crucial in reducing their morbidity and mortality rate. One of the tools to 
assist clinicians in predicting the requirement of blood transfusion is GBS. 
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Haemoglobin level (Hb) is one of the leading indicators to start RBC transfusion. However, the 
outcome of the Hb level upon discharge remains controversial. Discharge Hb is essential in clinical 
practice, and it can be a useful indicator in regulating the appropriateness of RBC transfusion. This 
study is to investigate discharge Hb level influences the outcome of patients with NVUGIB, hence 
improving patient blood management (PBM). Apart from that, it also evaluates the outcomes of 
two different groups of patients with lower and higher discharge Hb level. The evaluated outcomes 
include the number of RBC units transfused, length of stay (LOS) and adverse events (AE) after 
discharge.  
 
This study can be of benefit to transfusion services and other tertiary hospitals as these centres 
would be able to improve the current transfusion practice in NVUGIB patients. It can also enhance 
the current understanding of the risk-to-benefit profile of RBC transfusion. As a consequence, this 
study can be used as an instrument to increase the awareness of the potential complications linked 
with RBC transfusion. This in turn, encourages physicians to be more judicious in blood 
transfusion practice. In the long run, it could also potentially decrease the rising cost of healthcare 
services on transfusion services. 
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1.4 Research Objectives 
 
1.4.1 General Objective 
 
To evaluate the RBC transfusion requirement among patients admitted with NVUGIB. 
 
1.4.2 Specific Objectives 
 
i. To identify the demographic characteristics, risk factors, aetiologies and Forrest 
classification in NVUGIB patients. 
ii. To determine the associations between the number of RBC units transfused in NVUGIB 
patients with presenting symptoms, aetiologies and GBS. 
iii. To compare the outcomes in two groups of NVUGIB patients (lower discharge Hb and 
higher discharge Hb) with: 
a. Number of RBC units transfused 
b. Length of stay (LOS) 
c. Adverse events (AE) after discharge (Readmission, Rebleeding and Mortality) 
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1.5 Research Hypothesis 
 
i. There is an association between the number of RBC units transfused with presenting 
symptoms, aetiologies and GBS in NVUGIB patients. 
ii. There is an association between discharge Hb level with the number of RBC units 
transfused, LOS and AE after discharge. 
 
1.6 Conceptual Framework 
 
 
 
 
 
                                                       
 
 
 
 
 
 
 
 
Figure 1.1 Conceptual Framework 
Demographics Risk Factors Forrest Classification 
NVUGIB 
Discharge Hb • Presenting 
symptoms 
• Aetiologies 
• GBS  
Lower 
discharge Hb 
Aetiologies 
• Number of RBC units 
transfused 
• LOS 
• AE after discharge 
Higher 
discharge Hb 
Number of RBC units 
transfused 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Indication and predictive factors of RBC transfusion in NVUGIB 
 
Gastrointestinal bleeding is the most prevalent cause of hospitalisation due to gastrointestinal 
disease in the United States. It accounts for more than 507,000 hospitalisations and $4.85 billion 
annually (Peery et al., 2015). Acute UGIB is a common emergency condition linked with a high 
morbidity and mortality (Gralnek et al., 2008). It is also associated with high rate of RBC 
transfusion which accounts for 11% of all RBC transfused in England (Ferguson and Mitchell, 
2006). 
 
The mechanism involved in the development of NVUGIB is not entirely understood. The mucosal 
layer and submucosal blood vessels must be broken down for the bleeding to occur. Helicobacter 
pylori infection and/or NSAIDs or aspirin are commonly associated with the disruption of the 
mucosal layer. However, causes such as Mallory-Weis Syndrome, vascular lesions and neoplastic 
lesions can result in the exposure of blood vessels to the luminal content. Exposure of the 
underlying blood vessels to the action of acid and pepsin further erodes the vessel wall and 
interferes with blood coagulation (Lanas and Chan, 2017). 
 
In general, the purpose of RBC transfusion is mainly to improve oxygen delivery to the tissue with 
the target to correct or prevent hypoxia and intravascular volume replacement. RBC transfusion 
increases the Hb concentration of patients with acute or chronic anaemia, and this helps maintain 
the oxygen-carrying capacity of the blood (Murphy et al., 2002). RBC transfusion is a transitory 
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measure since the deficiency regresses unless the cause of bleeding is treated. Treatment must be 
individualised depending on factors such as age, symptoms, haemodynamics stability and 
concomitant illnesses (Murphy et al., 2002).  
 
In a local study, Lakhwani et al., investigated UGIB cases in HKL, involving a sample consisting 
of 88.3% male and 11.7% females. The mean age was found to be 51.9 years, of which 37.5% was 
in the > 60 years of age range. With regards to the ethnicity, 49.2% of the patients were Chinese, 
25.8% were  Malays,  23.4% were Indians and 3.1% of others (Lakhwani et al., 2000). Similar 
findings were found by Garrido et al., in which 76.41% of the UGIB patients were males while 
23.59% were females with a mean age of 60.45 (Garrido et al., 2006).  
 
Acute NVUGIB can present with haematemesis, melaena, haematochaezia or a combination of 
these symptoms. Haematemesis with bright red vomitus indicates acute haemorrhage while recent 
haemorrhage appears as “coffee ground” vomitus. The breaking down of haemoglobin in RBC 
into haematin by gastric acid results in the formation of coffee ground vomitus. Melaena refers to 
the black, tarry, loose or sticky and foul smelling stool resulting from the breakdown of blood in 
the intestine (Bouchier and Allan, 1993; Yamada and Alpers, 1995). Occasionally, a brisk UGIB 
manifests as haematochaezia which is also described as red or maroon stools. Patients presenting 
with brighter red stool indicates a shorter stool transit time (Laine and Shah, 2010). There is an 
association between the presenting symptoms and the transfusion risk. Haematemesis carries an 
Odds Ratio (OR) of 3.12, melaena carries an OR of 1.59 and haematochaezia carries an OR of 
33.17 (Garrido et al., 2006).  
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Studies on the association between aetiologies and the risk or requirement of blood transfusion are 
limited. However, a study by Garrido et al., found that there was a link between the aetiologies of 
NVUGIB and transfusion risk. Peptic ulcer carries an OR of 0.5, Mallory-Weis Tear with an OR 
of 0.34, angiodysplasia with an OR of 0.65, and other causes with an OR of 0.24 (Garrido et al., 
2006). In a local study in HKL, it was reported that 21% of peptic ulcer patients and 11% of 
patients with gastric erosions required RBC transfusion (Lakhwani et al., 2000). In a similar study 
by Garrido et al., the various aetiologies of UGIB were linked to different transfusion 
requirements. This is about the number of RBC units required. On average, gastric ulcer requires 
2.85 units, Mallory-Weiss tear requires  2.66 units, angiodysplasia requires 2.58 units, and UGIB 
of unknown origin requires 5.5 units of RBC (Garrido et al., 2006). 
 
Several scoring systems have been designed to establish the risk factors and outcome in UGIB 
patients. In one of the studies which compare the risk score in UGIB conducted in Glasgow, UK, 
the Glasgow-Blatchford Score (GBS) was found to be far more accurate in predicting blood 
transfusion as compared to Rockall Risk Score. The practice of using GBS to predict intervention 
and outcome following UGIB is becoming more common (Stanley et al., 2011). In another study 
by Shahrami et al., GBS was found to be a highly accurate scoring system in predicting the 
probability of rebleeding and the need for blood transfusion (Shahrami et al., 2018). GBS is more 
superior compared to other different scoring systems, AIMS65 in the detection of high-risk 
patients and those in need of blood transfusion (Yaka et al., 2015). According to a study by Stanley 
et al., GBS performs better than other scoring systems in predicting the need for intervention of 
endoscopic treatment (Stanley et al., 2017). A significant correlation was found between higher 
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GBS score and the increase in the need for at least one intervention which includes blood 
transfusion (Shahrami et al., 2018). 
 
2.2 Transfusion Practice in UGIB 
 
The decision to initiate blood transfusion must be individualised. For most patients, a blood 
transfusion will be initiated if the Hb is < 7 g/dl with a goal of maintaining Hb of ≥ 7 g/dl (Laine 
and Jensen, 2012). However, the goal is to maintain Hb ≥ 9 g/dl if the patients are at increased risk 
of suffering AE, in particular with unstable coronary artery disease or with evidence of active 
haemorrhage. This goal is established based on the patient’s comorbid condition and is 
independent of the patient’s age group. However, patients with active haemorrhage and 
hypovolemia may require RBC transfusion despite normal Hb level (Maltz et al., 2000). On the 
contrary, the current practice in Malaysia is to maintain a Hb level of approximately 10 g/dl 
according to the CPG. The indications to transfuse RBC in UGIB patients include SBP < 
110mmHg, postural hypotension, pulse rate > 110/min, Hb < 8 g/dl, and angina or cardiovascular 
disease with Hb < 10 g/dl (MOHM, 2003). Our current practice is supported by British Society of 
Gastroenterology guidelines which recommends RBC transfusion when the Hb is < 10 g/dl 
(Palmer, 2002). In a cluster randomised trial done in six hospitals in the UK, the indication for 
RBC transfusion in the restrictive strategy is when their Hb < 8 g/dl. Meanwhile, patients were 
eligible for RBC transfusion when their Hb is < 10 g/dl in the liberal strategy (Jairath et al., 2013). 
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Platelet transfusion is also one of the most common blood products used in UGIB patients. In 
general, patients with active bleeding and thrombocytopenia with a platelet count of < 50 000 x 
109/l should be transfused with platelets (Ramos et al., 2018). Similarly, based on the Malaysian 
CPG, platelet transfusion is indicated if the platelet count is < 50 000 x 109/l (MOHM, 2003). 
Interventional OGDS is warranted if the platelet count is < 20 000 x 109/l. However, patients with 
active haemorrhage require a platelet count of  ≥ 50 000 x 109/l before endoscopy (Laine, 2018). 
The benefit of platelet transfusion in patients who are on antiplatelets with UGIB still remains 
unclear, in fact, it may be potentially harmful. Hence, an individualised approach is necessary 
based on the complete clinical picture (Zakko et al., 2017).  
 
Patients with coagulopathy as a direct cause of UGIB with prolonged prothrombin time (PT) and 
INR > 2.0 should generally receive FFP transfusion. OGDS is usually performed once the INR is 
< 2.5 (Acosta et al., 2016). Urgent OGDS in patients who are haemodynamically stable should not 
be put on hold until the coagulopathy is corrected and can be done simultaneously with blood 
product transfusion (Wolf et al., 2007). A unit of FFP should be given after every four units of 
RBC transfusion as they do not contain coagulation factors (Maltz et al., 2000). PCC infusion is 
preferred for patients with life-threatening bleeding in which a more rapid reversal of coagulopathy 
can be achieved. The Malaysian CPG guideline on FFP transfusion in UGIB patients has yet to be 
updated. FFP transfusion is indicated if the PT is at least 1.5 times higher than the control value 
(MOHM, 2003). 
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2.3 Liberal and restrictive transfusion strategy in NVUGIB 
 
Transfusing RBC for anaemic patients is one of the most extensively utilised medical 
interventions. It is often driven by anxiety towards any level of anaemia regardless of the aetiology. 
The basis for RBC transfusion is evident in which low Hb could lead to reduced tissue perfusion, 
organ failure and mortality. Prevention of anaemia and more liberal RBC transfusion strategies 
were implemented at one point (Healthcare Cost and Utilization Project (HCUP), 2012). In a 1942 
report, the practice of transfusing when Hb level falls lower than 8-10 g/dl was initially suggested 
(Adams and Lundy, 1942). This was consequently generalised to medical and surgical conditions 
and incorporated into some guidelines including those for acute UGIB (Non-variceal upper 
gastrointestinal haemorrhage: guidelines, 2002). 
 
Several randomised trials have compared different strategies of transfusing patients with UGIB, 
specifically the restrictive and the liberal strategy. In the restrictive strategy, the transfusion Hb 
threshold was 7 g/dl with a target range for the post-transfusion Hb level of 7 to 9 g/dl. On the 
contrary, in the liberal strategy group, the transfusion Hb threshold was 9 g/dl with a target range 
for the post-transfusion Hb level of 9 to 11 g/dl (Villanueva et al., 2013). 
 
The restrictive strategy appeared to be potentially more advantageous than the liberal strategy in 
acute UGIB. There are still many uncertainties including the optimal trigger for transfusion, the 
effects of ongoing haemorrhage, administration of other blood components and patient 
comorbidities (Jairath et al., 2013; Villanueva et al., 2013). The explanation on why transfusion 
seems to worsen patients' outcome in certain circumstances remains unclear and requires further 
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research. It is possible that transfusion could increase the portal and/or systemic blood pressures, 
hence promoting further haemorrhage (Tsai et al., 2004). 
 
In the following years, there were no less than seven additional large Randomised Control Trials 
(RCTs) assessing patients with various medical and surgical conditions were published. For all the 
RCTs, each was comparing restrictive strategy to the liberal strategy. Nonetheless, only two of 
those RCTs centralised on patients with acute UGIB (Jairath et al., 2013; Villanueva et al., 2013). 
A multicenter cluster-randomised pilot study of restrictive versus liberal strategy in the UK 
followed involving 936 patients with UGIB of any aetiology from 6 different hospitals. There were 
no significant differences regarding 28-day mortality or rebleeding comparing both transfusion 
strategies. These data are crucial and have contributed to the updated transfusion recommendations 
in UGIB patients. However, additional studies are required to support this (Barkun et al., 2010; 
Laine and Jensen, 2012).  
 
A meta-analysis of five RCTs concluded that patients with UGIB who were assigned to a 
restrictive strategy had a lower risk of mortality and rebleeding as compared to those assigned to 
a liberal strategy.  There was no association between the risk of mortality with the different 
strategies applied in patients with ischaemic heart disease (IHD). However, in patients without 
IHD, the risk of mortality was lower when the restrictive strategy was applied. The risk of 
rebleeding remains similar in both groups of strategies, in patients with or without IHD. There 
were no significant differences on the risk of myocardial infarction, stroke and acute kidney injury 
between a restrictive and liberal strategy in the meta-analyses (Ayodele et al., 2017). 
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Nonetheless, it is essential to avoid the postulation that the liberal strategy is detrimental to the 
patients. Apparently, in some patients with rapid UGIB haemorrhage, blood transfusion remains a 
lifesaving intervention (Perel et al., 2014). Massive haemorrhage with haemorrhagic shock could 
trigger different physiological processes and responses which requires specific treatment (Cannon, 
2018).  The current guideline for the recommended Hb cut-offs level is reasonable. However, since 
Hb alone is not an accurate indicator to measure the extent of the tissue oxygenation particularly 
in the setting of acute blood loss, it should be approached with caution. For this reason, clinicians 
should not consider absolute Hb values as the only parameter for transfusion decisions (Yen, 
2018). 
 
Patient blood transfusion management (PBM) aims to improve patient outcome and to reduce cost 
related to blood transfusion (Waters and Ness, 2011). PBM involves evidence-based practices 
primarily to manage anaemia, haemostasis and blood loss and to improve the outcomes of patients 
(WHA Resolution 63.12, 2011). The establishment of PBM programs was mainly to improve blood 
utilisation since restrictive transfusion strategy results in improved patient safety and reduced costs 
(Shander and Goodnough, 2010). Over the past half century,  PBM has been pointed out as one of 
the ten critical advances in transfusion medicine (Goodnough and Shander, 2012).  
 
Despite advances in proper blood management, 23% of RBC unit transfusions appear to be 
inappropriate. This applies most common among younger patients, who underwent surgery with 
lower comorbidity and those with higher Hb. This study also indicates the absence of awareness 
among a significant minority of clinicians who are reluctant to accept lower transfusion thresholds. 
Transfusion practice could be further improved by exploring the obstacles to the implementation 
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of recommended transfusion threshold and developing guidelines on appropriate post-transfusion 
Hb level (Barr et al., 2011). 
 
A discharge Hb level of ≥ 10 g/dl in a hospitalised patient who was transfused with RBC could 
indicate unnecessary transfusion. Post-transfusion Hb level of ≥ 9 g/dl has not been proven to be 
associated with an added advantage. Several factors which include comorbidities, LOS, treatments 
given and transfusion of RBC units could influence the patient’s Hb at discharge (Edwards et al., 
2012). One of the factors for an appropriate PBM that could be proposed is discharge Hb level of  
≥ 10 g/dl (Barr et al., 2011). A more stringent target could even be proposed by considering a 
discharge Hb of ≥ 9 g/dl as an indication of overtransfusion (Edwards et al., 2012).  
 
2.4 Outcome of discharge Hb in association with RBC units transfused, LOS and AE after 
discharge 
 
Hb value within 24 hours before discharge is referred to as the “discharge Hb”. It is an essential 
concept in clinical practice that can be a useful indicator in evaluating the suitability of RBC 
transfusion (Edwards et al., 2012). There is limited study done to evaluate the clinical outcomes 
based on the discharge Hb level (Lee et al., 2016). The cut-off point for discharge Hb level was 
taken as 10 g/dl because Hb level should be maintained at a level of approximately 10 g/dl 
(MOHM, 2003). The lower discharge Hb level refers to <10 g/dl while the higher Hb discharge 
level refers to ≥ 10 g/dl. Even though several studies have been conducted on the transfusion 
strategies in patients with UGIB, there was no specific study on the relationship between discharge 
Hb and the outcome (Lee et al., 2016).  
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LOS refers to the length of an inpatient episode of care, calculated from the day of admission to 
day of discharge, and based on the number of nights spent in a hospital. Patients admitted and 
discharged on the same day have a length of stay of less than one day (Segen's Medical Dictionary, 
2012). The average LOS in hospitals is often used as an indicator of efficiency (Health at a Glance, 
2011). AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject who has been administered an intervention. This does not necessarily have a causal 
relationship with this treatment (In Guideline for Good Clinical Practice, 1996).  
 
In a study by Lee et al., comparing the lower and higher discharge Hb group, the former received 
a lower number of RBC units (Lee et al., 2016). In another study by Villaneuva et al., a similar 
finding was found in which patients received a lower number of RBC units in the lower Hb group 
(Villanueva et al., 2013). There were no significant differences in the LOS comparing the two 
groups of patients (Lee et al., 2016). However, in a study by Villanueva et al., those in the lower 
Hb group had shorter LOS (Villanueva et al., 2013).  The differences in the AE after discharge 
between both groups were not significant. The AE after discharge in this context refers to 
readmission, rebleeding and mortality (Lee et al., 2016). However, the risk of rebleeding and 
mortality was found to be significantly reduced in the lower Hb group (Villanueva et al., 2013). 
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CHAPTER 3: METHODOLOGY 
 
3.1 Study design 
 
This was a retrospective cohort study composed of data from selected patients who fulfil the 
inclusion criteria. One hundred eighty patients who underwent OGDS and received at least one 
unit of RBC over a period of 5 years (2012 to 2017) were selected for this study. Systematic 
random sampling was used to choose study subjects after the data cleaning process according to 
the inclusion and exclusion criteria stated in sections 3.5 and 3.6. All demographic and clinical 
data related to risk factors of NVUGIB, presenting symptoms, aetiologies, Forrest classifications, 
GBS, AE were captured in Appendix 1. The selected patients were classified according to the level 
of Hb upon discharge. They were divided into two groups, Hb discharge level of < 10 g/dl and ≥ 
10 g/dl. 
 
3.2 Data Collection Method 
 
Data of the selected cases were retrieved from computerised patient data system (patient medical 
record) of Hospital Putrajaya. Patients were chosen using systematic random sampling. Every fifth 
patient in the medical record arranged in the sequence of dates of the year was chosen. This was 
done on a clean set of data, starting from the fifth patient in the list. Sample size calculation was 
as shown in 3.4. The data retrieved were then filled in the proforma.  
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3.3 Study duration 
 
Study duration period was from 1st January 2017 to 31st December 2018 (24 months).  
 
3.4 Sample size 
 
For objective 1 
 
A computer software PS: Power and Sample Size Calculation version 3.0, 2009, was used to 
calculate sample size (Dupont and Plummer, 1997). The formula used for sample size calculation 
was two proportion. The relevant values for sample size estimation were based on a study by 
Garrido et al., 2006.  For the proportion of RBC transfused among NVUGIB, the power of this 
study was set at 0.8 with CI of 95% (α = 0.05). The proportion of non-transfused group among 
NVUGIB was 0.3 (P0), and the proportion of transfused group was 0.7 (P1). The ratio of control to 
experimental subjects was set at 1 (m). Therefore, the sample size calculated was 51. 
 
For objective 2 
 
The sample size was in accordance with objective three as it was calculated as the highest sample 
size in the particular study. 
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For objective 3 
 
A computer software PS: Power and Sample Size Calculation version 3.0, 2009 (Dupont and 
Plummer, 1997) was used to calculate the sample size. The formula used for sample size 
calculation was independent T-test in which the estimated sample size was based on the mean 
difference. The relevant values for sample size estimation were based on a study by Lee et al., 
2016. For the correlation between discharge Hb level in NVUGIB patients and the number of RBC 
units transfused, the power of this study was set at 0.8 with CI of 95% (α = 0.05). In a previous 
study based on Lee et al., 2016, the response within each subject was normally distributed with a 
standard deviation of 1.8 and a mean difference of 0.8. The largest sample needed was 80 in a 
single group, and 160 samples were needed for both groups. 10% of additional participants were 
added to cover the possibility of incomplete data. Therefore, the sample size calculated was 172. 
 
3.5 Inclusion Criteria 
 
i. Age of 18 years old or more 
ii. Patients admitted to the ward 
iii. Patients transfused with any unit of RBC 
iv. Patients with NVUGIB exclusively 
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3.6 Exclusion criteria 
 
i. Patients with variceal bleeding 
ii. Patients who were given a follow-up on an outpatient basis 
iii. Patients who had undergone OGDS in daycare. 
iv. Patients with concurrent Lower Gastrointestinal Bleeding (LGIB)  
v. Patients who developed two or more bleeding episodes before discharge. 
 
3.7 Statistical analysis 
 
SPSS version 24.0 for Windows software (SPSS, Chicago Illinois, USA) was used to perform the 
statistical analysis to present the descriptive and statistical analysis. Number, percentage, mean 
and median were used in the descriptive analysis. 
 
For objective 1 
 
Demographic data were shown using number and percentage for the number of patients, gender, 
ethnicity, risk factors, aetiologies of NVUGIB and Forrest classification. Meanwhile, for age and 
LOS, mean and standard deviation were used. The data for age was normally distributed while for 
LOS, it was not normally distributed. Komolgorov-Smirnov was used for the test for normality.  
The level of significance was set at a p-value of 0.05. 
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For objective 2 
 
The distribution for the number of RBC units transfused for the samples was not parametric. 
Hence, in order to test the difference of mean for RBC units transfused across groups of presenting 
symptoms and aetiologies, Mann-Whitney U was used as a non-parametric test. Meanwhile, the 
Pearson Correlation Coefficient was used to determine the association between GBS with RBC 
units transfused in NVUGIB patients. Simple linear regression was used to establish the 
relationship between GBS and the number of RBC units transfused. Multiple linear regression was 
used to determine the association between presenting symptoms, aetiologies and GBS with RBC 
units transfused. The level of significance was set at a p-value of 0.05. 
 
For objective 3 
 
Mann-Whitney test was used to determine the independent impact of discharge Hb group with 
RBC units transfused and LOS since they were not a normally distributed data. Meanwhile, 
Pearson Chi-Square test is used to determine the impact of discharge Hb group with the AE after 
discharge (readmission, rebleeding and mortality). The level of significance was set at a p-value 
of 0.05 
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3.8 Flow Chart of Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Flow chart of study 
 
Reference Population 
NVUGIB patients in Hospital Putrajaya 
Source Population 
NVUGIB patients in Hospital Putrajaya 
who received minimum 1 unit of packed 
RBC and underwent OGDS  
Meet the inclusion criteria 
Study sample 
n = 180 
Data Collection 
Systematic random 
sampling of every 
fifth patients by 
order of date of 
OGDS done 
Data entry, analysis by SPSS, interpretation and report 
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3.9 Definition of the terms used 
 
i) Length of Stay (LOS) is defined as the length of an inpatient episode of care, calculated 
from the day of admission to day of discharge. However, in this study LOS specifically 
refers to the time when UGIB symptoms started until the time of discharge from the 
hospital. 
ii) Adverse Events (AE) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject who has been administered an intervention. However, in this study, 
AE refers to patients who were readmitted after they have been discharged after the episode 
of NVUGIB. 
iii) Readmission refers to patient admission to the hospital due to any reasons within 45 days 
after the episode of NVUGIB. 
iv) Rebleeding refers to patients who were discharged, readmitted, and developed another 
bleeding episode. This bleeding episode was characterised by haematemesis or fresh 
melaena associated with haemodynamic instability (pulse rate of > 100 beats per minute, 
SBP < 100 mmHg, or both) after the episode of NVUGIB. 
v) Mortality refers to patients who were discharged, readmitted and died due to any cause 
within 45 days after the episode of NVUGIB. 
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3.10 Ethical Approval 
 
Ethical approval with the reference number of NMRR-17-139-34033 was obtained from Ministry 
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Committee). In addition, ethical approval with the reference number of USM/JEPeM/17020127 
was obtained from Jawatankuasa Etika Penyelidikan Manusia USM (JEPeM). All the data were 
retrieved from patient’s medical record and the data were recorded with reference identification. 
The desired medical record data was recorded in such a way that the respective patients could not 
be identified either directly or indirectly via linkage codes assigned to the data. Thus, the data that 
was collected is completely anonymous. The use or disclosure of protected health information 
involves no more than a minimal risk to the privacy of individuals. 
 
 
 
 
 
 
 
 
 
 
 
 
